
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc is well-positioned for growth, as evidenced by the significant 587% increase in prescriptions for GLP-1 drugs to treat overweight or obesity from 2019 to 2024, highlighting a rising market demand for effective metabolic disease treatments. The company's focus on developing durable, disease-modifying therapies that target the root causes of type 2 diabetes and obesity is supported by the demonstrated effectiveness of GLP-1 PGTx, which offers greater improvements in blood glucose and weight control compared to existing treatments. Furthermore, Fractyl's current manufacturing capabilities are expected to be adequate to support the advancement of its first-in-human Phase 1 trial, with anticipated scalability as the program develops, underscoring the company's potential to capitalize on market opportunities.
Bears say
Fractyl Health Inc. demonstrates potential in improving HbA1c levels among type 2 diabetes patients; however, the financial aspect indicates a troubling trend. The company's increasing cash burn due to the expansion of development and commercial programs raises concerns about its sustainability, despite the possibility of offsetting this cost with milestone revenue from partners. Additionally, the inherent challenge of addressing the gradual loss of β-cell function in T2D patients suggests that achieving long-term therapeutic efficacy may be more complex and resource-intensive than anticipated, further complicating Fractyl's financial outlook.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares